Søren Møller, Ph.D.

Bio:

Søren Møller is Managing Partner of Seed Investments at Novo Holdings. In this role, he leads Novo Holdings’ company-creation and seed investments in biotech and biopharma. He also oversees Novo Holdings’ Quantum and Antimicrobial Resistance portfolios.

Prior to joining Novo Holdings, Søren served as Global Manager of Genomics at Novozymes A/S. Earlier, Søren was CSO and VP of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO, and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as Head of Lead Identification at BioImage and as research scientist at Novo Nordisk.

Søren currently serves on the boards of directors of Reapplix, Orbis Medicines and Northsea Therapeutics. Since 2008, Søren has been a Board Member of Danish Biotech and Active Owners Denmark.

Søren holds an MSc and PhD in molecular biology, both from the Technical University of Denmark, and trained as postdoctoral fellow at Stanford University School of Medicine.